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ABSTRACT
Background. The next step in breast-conserving surgery
for small breast carcinomas could be local ablation. In this
study, the feasibility of ultrasound-guided laser-induced
thermal therapy (LITT) is evaluated.
Methods. Patients with large-core needle biopsy-proven
invasive, palpable breast carcinoma (clinically B2 cm)
underwent ultrasound-guided LITT, followed by surgical
excision. Completeness of ablation was determined by both
hematoxylin and eosin staining and nicotinamide adeno-
sine diaphorase staining.
Results. Fourteen patients completed the treatment. The
mean histological tumor size was 17 mm (range, 8–
37 mm); 6 of 14 tumors were histologically larger than the
clinical entry threshold of 2 cm. The power applied in all
patients was 7 W, and the mean treatment time was 21.4
min (range, 15–30 min). In one patient, a skin burn
occurred, and one patient had a localized pneumothorax
that could be treated conservatively. In 7 (50%) of 14
patients, the tumor was completely ablated, as conﬁrmed
by nicotinamide adenosine diaphorase staining. In 11
cases, extensive in-situ carcinoma was present. In one case,
the in-situ carcinoma was also completely ablated. A total
of seven (88%) of eight tumors\2 cm in size were com-
pletely ablated versus one (17%) of six tumors that were
C2 cm in size (P = .026).
Conclusions. Successful LITT of invasive breast cancer
seems to be feasible when conﬁned to small (\2 cm)
nonlobular carcinomas without surrounding extensive in-
situ component and angioinvasion. However, to implement
LITT in a curative setting, improvements in imaging to
more reliably preoperatively assess tumor size and moni-
toring of ﬁber tip placement and treatment affect are
essential.
Over the past decades, there has been a transition from
extensive oncological surgery to minimally invasive onco-
logicalsurgery.Inthetreatmentofbreastcarcinomas,clearly
the transition from the radical Halsted operation to breast-
conserving surgery (BCS) and adjuvant radiotherapy for the
small carcinomas was a great improvement.
1–3 The intro-
duction of the sentinel node procedure isin line with the aim
at minimally invasive surgery.
4 As a result of the extensive
screeningprogramsforbreastcancer,theproportionofsmall
breast carcinomas has increased.
5 Especially for this group
of patients with early breast cancer, there is still room for
improvement of the treatment. The cosmetic outcome of
BCSisoftendisappointing,andBCScarriesarelativelyhigh
morbidity rate mainly due to postoperative bleeding (up to
11%) and infections (3% to 4%).
6–8 As a result of surgical
complications,adjuvanttreatmentmaybedelayed,affecting
the outcome unfavorably.
9
The next step in BCS could be local ablation of small
breast carcinomas, provided it is equally effective but with
fewer complications and a better cosmetic outcome than a
lumpectomy. Local ablation should efﬁciently and com-
pletely destroy the invasive breast carcinoma and
surrounding in-situ carcinoma. Currently, cryosurgery,
radiofrequency ablation, laser-induced thermal therapy
(LITT), microwave ablation, and high-intensity focused
ultrasound ablation are clinically available local ablation
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10–15 In all of these modalities, a change in
temperature is used to lethally damage the intracellular
DNA binding structures, thereby causing cell death.
16,17
LITT requires a laser ﬁber to guide the light energy directly
into the tissue to be treated. Upon absorption in the tissue,
heat is produced, inducing lethal thermal injury. At present,
LITT and radiofrequency ablation are mostly used to treat
unresectable colorectal liver metastases as an alternative to
surgery.
18,19 The results are promising, and possibly in the
future, these modalities could also be used for the local
ablation of breast carcinoma in a curative setting.
To implement this minimally invasive approach, several
steps need to be taken. First, the exact tumor size should be
reliably assessed. Second, the treatment should be safe and
able to completely destroy all tumor tissue (including in-
situ cancer) locally. Finally, a reliable real-time way to
monitor the treatment results should be available.
In this feasibility study, we evaluated the second
prerequisite by ultrasound-guided LITT for local treat-
ment of patients with clinically small palpable breast
carcinomas.
MATERIALS AND METHODS
The study was approved by the medical ethical com-
mittee of our hospital. All patients had a palpable invasive
breast carcinoma diagnosed by an ultrasound-guided large-
core needle biopsy (LCNB). The tumor characteristics (i.e.,
grade, estrogen receptor status, progesterone receptor sta-
tus, HER-2/neu status, and mitotic activity index) were
preoperatively determined on the LCNB.
Inclusion criteria were age[18 years, palpable cT1 (as
measured by preoperative ultrasound and mammography),
unifocal invasive breast carcinoma, tumor visible on
ultrasound, preoperative tumor characteristics available,
and distance of C1 cm from the thoracic wall and the
overlying skin.
A sentinel lymph node biopsy (SLNB) was performed
before the LITT procedure. For the SLNB, four depots of a
total of 120 MBq
99mTc nanocolloid were injected peritu-
morally, and static images were acquired up to 4 h after
injection. Peroperatively, 1 mL of patent blue (Bleu
patente ´ V ‘‘Guerbet’’) was injected peritumorally. The
exact tumor size was measured in two dimensions after the
SLNB by ultrasound (Philips, iU22 scanner, equipped with
an 8 MHz linear array transducer).
Next, a 17-gauge guidance needle (Bard Truguide,
Covington, United Kingdom) was placed into the center of
the tumor. The position of the needle was checked ultr-
asonographically in three dimensions. Both the tumor size
assessment and the placement of the guidance needle were
performed by a dedicated breast radiologist.
Next, an uncooled Microdom LITT laser ﬁber with an
active length of 2.5 cm was inserted into the tumor and
attached to an Nd:YAG continuous laser of 1045 nm (KLS
Martin, Umkirch, Germany). After conﬁrming the exact
position, the guidance needle was retracted to avoid heath
conduction to the skin and the procedure commenced. The
amount of energy needed to fully ablate the tumor was
determined in an experimental ex vivo setting in bovine
udder tissue. The maximum tumor size determined the
amount of energy that was used.
After the ablation, a wide local excision or mastectomy
was performed according to local practice.
At pathology, the margins of the specimen were inked
and the specimen was sliced in 5-mm slices. The macro-
scopic lesion size was recorded, and samples were taken
from the center of the coagulated area and the transition
zone between tumor and tumor-free margin (Fig. 1). The
samples were snap frozen and embedded in parafﬁn. Both
hematoxylin and eosin staining of parafﬁn-embedded sec-
tions and nicotinamide dinucleotide adenosine diaphorase
(NADH) staining of the frozen sections were used to
determine tumor vitality after ablation. Participating
patients underwent routine outpatient follow-up and stan-
dardbreastradiotherapyasapartofBCS.Onthebasisofthe
status of the sentinel node and primary tumor characteris-
tics, patients underwent an additional axillary dissection
and/or adjuvant chemotherapy.
RESULTS
Fourteen patients completed the LITT procedure.
Baseline characteristics are summarized in Table 1.
Most of the tumors (50%) were located in the upper lat-
eral quadrant of the breast, and 12–14 tumors were invasive
ductal carcinomas. All patients underwent a SLNB before
ablation; in 13 (93%)of 14, the sentinel node was found. Six
patients had axillary metastases, with isolated tumor cells in
FIG. 1 Macroscopic view of ablated tumor tissue. Outer circle
indicates the ablation zone; inner circle shows ﬁber track
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patients with axillary isolated tumor cells chose not to
undergo an additional axillary dissection. The three patients
with macrometastases all underwent additional axillary
dissection.
LITT time ranged from 15 to 30 min (mean, 21.4 min).
Thepowerappliedwas7 W(2.8 W/cmdiffuserlength)inall
cases. The mean ultrasound-measured tumor size was
15.3 mm, and the median ultrasound-measured lesion size
(Figs. 1 and 2) after ablation was 18 mm (range, 9–22 mm).
In all patients, extensive air bubble formation around the
ﬁber tip was observed on ultrasound. The maximum diam-
eter of the largest histological lesion size was 30 mm. The
median histological tumor diameter was 17 mm (range,
8–37 mm), and the median histological ablated tumor
diameter was 23 mm (range, 2–35 mm). In total, 7 (50%) of
14 of the invasive tumors were completely ablated, as con-
ﬁrmed by NADH staining. In 11 cases, an extensive in-situ
component surrounded the tumor, and in 1 case, this in-situ
component was also completely ablated. In 2 (14%) of 14
cases, only a very small component of the tumor seemed to
beablatedasaresultofmisplacementoftheguidanceneedle.
Two tumors had an extensive angioinvasive growth pattern,
resulting in preoperative underestimation of tumor size.
The invasive carcinomas that were histologically\2c m
in size were signiﬁcantly more frequent completely ablated
(7 of 8, 88%) than the invasive carcinomas that were
[2 cm in size (1 of 6, 17%) (P = .026).
In one patient, a superﬁcial skin burn occurred during
the procedure. This was treated with a partial skin resection
as a part of the lumpectomy. In another patient, the guid-
ance needle was placed close to the pectoral muscle,
resulting in a localized pneumothorax that could be treated
conservatively.
All but one patient had subsequent BCS. One patient
preferred breast amputation to avoid radiotherapy; this
patient experienced postoperative bleeding that could be
treated conservatively. A postoperative wound infection
occurred in two patients.
DISCUSSION
The aim of this study was to assess the feasibility of
ultrasound-guided LITT in invasive breast cancers clini-
cally up to 2 cm in size. Overall, the invasive breast cancer
was completely ablated in 7 (50%) of 14 patients. There
was a clear association between the success rate of LITT
and tumor size: cancers were completely ablated in seven
(88%) of eight and one (17%) of six of patients with a
carcinoma \2 cm and C2 cm, respectively. Our results
thereby show that LITT can completely ablate small
invasive breast carcinomas.
Previous studies have conﬁrmed the importance of tumor
size in completely ablating breast carcinomas.
15,20 There
were three reasons for the discrepancies between the
clinically/radiologically estimated tumor size and the his-
tological tumor size. First, two tumors showed a lobular
growth pattern. It is well known that tumor size for this type
of tumor is more difﬁcult to assess, and often this type of
tumor is histologically more extensive than estimated as a
result of their diffuse growth pattern.
21 In our opinion,
tumors showing lobular differentiation should therefore be
excluded from local ablation treatment in a curative setting.
Second, in 10 of 14 cases, extensive ductal carcinoma-in-
situ (DCIS) was present outside the ablation zone.
TABLE 1 Baseline patient characteristics
Characteristic Value
Median age (y) (range) 54.5 (35–85)
Median ultrasound tumor size (mm) (range) 14.5 (9–20)
Median histological tumor size (mm) (range) 17 (8–37)
Tumor location, n (%)
Upper lateral 7 (50)
Lower lateral 3 (22)
Lower medial 2 (14)
Retroareolar 2 (14)
Tumor histology, n (%)
Ductal carcinoma 12 (86)
Lobular carcinoma 1 (7)
Ductolobular carcinoma 1 (7)
SLNB found tumor, n (%) 13 (93)
SLNB free of tumor, n (%) 7 (50)
Breast-conserving surgery, n (%) 13 (93)
Mastectomy, n (%) 1 (7)
SLNB sentinel lymph node biopsy
FIG. 2 Microscopic view of ablation zone (hematoxylin and eosin;
original magniﬁcation, 925). Arrow indicates position of laser-
induced thermal therapy probe
Ultrasound-Guided Laser-Induced Thermal Therapy 2261Incompletely ablated DCIS may later well give rise to an
invasive recurrence, although radiotherapy helps to control
this. Invasive carcinomas showing extensive DCIS on
LCNB should be excluded from local ablation in a curative
setting as well. Third, in two patients, extensive angioin-
vasive growth was present, which was not seen on the
LCNB in one patient. These growth patterns cannot be
detected by mammography and/or ultrasound.
22–25 There-
fore, to arrive at successful LITT, preoperative tumor size
assessment needs to be improved. To this end, magnetic
resonance imaging (MRI) is likely to be the ﬁrst option,
although optical imaging may prove to be important in the
future.
26,27
To implement LITT as the breast-conserving treatment
for small carcinomas of the breast, reliable intraoperative
imagingisalsoneededduringtheLITTproceduretomonitor
placement of the laser ﬁber and the effect of treatment. The
importance of monitoring the placement ﬁber is emphasized
by an example: in one patient, a localized pneumothorax
occurred as a result of misplacement of the guidance needle.
Pneumothorax is a known complication after LCNB, but so
far, it is has not been described as a complication of mini-
mally invasive treatment of breast carcinoma.
28 Finally,
adequate imaging is vital to the treatment monitoring. In
mostofthestudiesperformedonLITTofbreastcarcinomas,
the treatment parameters were predetermined.
11,29 When
treatment parameters are predetermined, possible cooling
effects of blood ﬂow and differences in density of breast and
tumortissuecannotbetakenintoaccount,possiblyleadingto
undertreatment of the tumor tissue. Real-time monitoring
and adjusting of the treatment parameters would be ideal. In
this study, the progress of the ablation was monitored by
ultrasound. Temperatures close to the ﬁber tip reach 100C,
causing evaporation of the tumor tissue (Fig. 2).
29,30 This
evaporation causes hyperechoic air bubbles, making ultra-
sound monitoring difﬁcult.
31 Nevertheless, the temperature
inthefattytissuesurroundingthetumorincreasesslowlyand
is lower, possibly resulting in less fatty necrosis and there-
fore a better cosmetic outcome and less reinterventions.
32
Although not clinically available yet, real-time magnetic
resonance–guided thermal mapping is a promising new
technique that could become a good alternative to ultra-
sound.
33 Because LITT causes ablation through the
absorption of light energy, it can be monitored by MRI,
whereas radiofrequency ablation is based on radiofrequent
waves,causingartifactsinMRIthatmakeMRImonitoringa
challenge.
34
Determination of the sentinel node via SLNB is
important for adequate staging and further treatment.
Possibly local ablation of the tumor tissue disturbs the
lymph drainage pattern. Therefore, in this study, the SLNB
was performed directly before the LITT procedure. In 13
(93%) of 14 patients, the sentinel node was detected and
collected—a rate comparable to that described in the cur-
rent literature.
35 In available studies on LITT to date, no
clear data have been provided on the timing of the SLNB.
Besides the pneumothorax in one patient, another
patient had a skin burn that could easily be treated. Other
complications described in literature, such as gaseous
rupture of tumor tissue and hyperemia, were not observed
in this feasibility study.
11,15,30
The NADH staining conﬁrmed the hematoxylin and
eosin staining results in all cases. As has been shown in
other studies, NADH is a reliable stain to conﬁrm tissue
vitality. NADH staining requires tissue to be snap frozen,
which can be impractical in a routine clinical setting.
Cytokeratin 8/18 could be a good and practical alternative
because it does not requires tissue to be snap frozen.
10
In conclusion, successful LITT of invasive breast cancer
seems to be feasible when conﬁned to small (\2 cm)
nonlobular carcinomas without a surrounding extensive in-
situ component and angioinvasion. However, to implement
LITT in a curative setting, it will be essential to improve
imaging to more reliably preoperatively assess tumor size
and to monitor ﬁber tip placement and treatment effect.
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